NET ASSET VALUE – 28 February 2025
On the 28 February 2025 Flerie AB's Net Asset Value (NAV) was SEK 4,063 million and NAV per share was SEK 52.05.
|
Allocation of NAV |
Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 476 | 6.09 | 11.7% |
| Xspray Pharma | 18% | 209 | 2.68 | 5.2% |
| Empros Pharma | 79% | 204 | 2.62 | 5.0% |
| KAHR Medical | 31% | 203 | 2.60 | 5.0% |
| Lipum | 57% | 196 | 2.51 | 4.8% |
| Atrogi | 37% | 176 | 2.25 | 4.3% |
| Xintela | 61% | 162 | 2.08 | 4.0% |
| Microbiotica | 10% | 135 | 1.73 | 3.3% |
| Geneos Therapeutics | 12% | 103 | 1.32 | 2.5% |
| Mendus | 24% | 95 | 1.21 | 2.3% |
| AnaCardio | 14% | 69 | 0.89 | 1.7% |
| Toleranzia | 66% | 67 | 0.86 | 1.6% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.71 | 1.4% |
| Synerkine Pharma | 43% | 55 | 0.71 | 1.4% |
| Vitara Biomedical | 10% | 54 | 0.69 | 1.3% |
| Egetis Therapeutics | 2% | 29 | 0.37 | 0.7% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,383 | 30.53 | 58.6% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.7% |
| Symcel | 31% | 174 | 2.23 | 4.3% |
| Chromafora | 31% | 73 | 0.93 | 1.8% |
| Nanologica | 43% | 72 | 0.92 | 1.8% |
| A3P Biomedical | 8% | 46 | 0.59 | 1.1% |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Provell Pharmaceuticals* | 72% | 0 | 0.00 | 0.0% |
| Total | 589 | 7.54 | 14.5% | |
| Limited Partnerships, total | 85 | 1.08 | 2.1% | |
| Assets related to Portfolio companies | 245 | 3.14 | 6.0% | |
| Other assets and liabilities | 761 | 9.75 | 18.7% | |
| Net asset value | 4,063 | 52.05 | 100.0% | |
* indirect shares in Provell Pharmaceuticals